佐力藥業(300181.SZ)：2019年淨利預增34.93%-63.84%
格隆匯1月22日丨佐力藥業(300181.SZ)披露2019年度業績預告，公司預計2019年1-12月歸屬於上市公司股東的淨利潤為2800.00萬元—3400.00萬元，同比增長34.93%—63.84%；歸屬於上市公司股東的淨利潤(未計提商譽和存貨減值準備)4600.00萬元-5200.00萬元，同比增長121.67%-150.58%。
報告期內，公司積極面對外部環境的變化，聚焦主業，以核心產品烏靈膠囊、百令片、靈澤片進入國家基本藥物目錄為契機，穩自營，強招商，加大市場投入和終端醫療機構開發覆蓋，主營業務收入穩步增長，公司預計2019年度實現歸屬於上市公司股東的淨利潤較上年同期增長34.93%-63.84%。
(一)報告期內，國家基本藥物政策的落地和實施給公司帶來了良好的發展機會，公司營銷變革初見成效，烏靈膠囊、百令片銷售增長率均超過35%；截至2019年12月底，烏靈膠囊在銷醫院數量(包括三級醫院、二級醫院、一級醫院及其他醫院)從3858家增加到6000多家，百令片在銷醫院數量從1491家增加到2700多家，為未來可持續增長奠定了基礎；
(二)報告期內，公司收回了德清醫院全部投資款及利息費，增加了當期利息收入416萬元；
(三)中藥配方顆粒業務尚處於推廣和市場拓展階段，未達到盈虧平衡。2020年，中藥配方顆粒國家標準有望出台，公司圍繞“提質量、降成本、拓市場”開展各項工作，努力將配方顆粒業務培育成新的利潤增長點；
(四)公司控股子公司佐力百草中藥為擴大產能增加了固定資產投資，導致折舊和財務成本增加，同時跟少數股東的股權糾紛也影響了中藥飲片業務的經營業績完成，導致虧損和商譽減值。2020年，中藥飲片業務板塊將抓住國家促進中醫藥傳承創新發展的機遇，努力提升生產與服務能力，拓展市場；
(五)公司將根據本年度經營情況及未來經營計劃對商譽、存貨進行減值測試，根據減值測試結果計提減值準備並計入減值損失，最終金額將由公司聘請的具有相關專業資質的評估機構及審計機構進行評估和審計後確定；
(六)報告期內，非經常性損益對公司淨利潤的影響金額約為713萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
